A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.
In February, the USPTO's Patent Trial and Appeal Board stopped UC's bid for IP underpinning the most lucrative applications of genome editing.
The plaintiffs say the USPTO made several errors when it determined the Broad Institute had the right to patent the use of CRISPR/Cas9 in eukaryotes.
Two Australian organizations are appealing a patent covering much of the cattle genome, according to ABC.
Arti Rai and Colleen Chien are studying whether the Supreme Court's decisions in Mayo v Prometheus and Bilski v Kappos have had a negative impact on diagnostics innovation.
Beef producers in Australia are fighting a bovine genome patent awarded to US companies, the ABC reports.
The USPTO has become involved in the CRISPR-Cas9 patent dispute.
A court of appeals will not reconsider the validity of Sequenom's '540 patent, saying it is bound by previous cases regarding patenting laws of nature.
The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.
The Australian High Court rules that isolated genetic material cannot be patented.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.